Xenon Pharmaceuticals (XENE) to Offer Common Stock

Xenon Pharmaceuticals Inc. (Nasdaq: XENE) announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors that so choose, pre-funded warrants to purchase common shares, pursuant to its existing shelf registration statement. It is expected that the underwriters of the offering will be granted an option for a period of 30 days to purchase up to an additional 15% of the common shares offered in the offering, at the public offering price, less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.

Jefferies, Stifel, and William Blair are acting as joint book-running managers for the offering. Needham & Company and Wedbush PacGrow are acting as co-managers for the offering.

You May Also Be Interested In

• Standard Nuclear prices IPO at $15 per share on NYSE
• Karooooo Ltd. (KARO) PT Raised to $70 at Needham
• IPG Photonics (IPGP) Reiterated at Buy by Stifel as Lumibird Acquisition Announced